Cardiogenic Shock - Pipeline Review, H2 2011

Global Markets Direct, November 2011, Pages: 24

Cardiogenic Shock - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Cardiogenic Shock - Pipeline Review, H2 2011', provides an overview of the Cardiogenic Shock therapeutic pipeline. This report provides information on the therapeutic development for Cardiogenic Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiogenic Shock. 'Cardiogenic Shock - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cardiogenic Shock.
- A review of the Cardiogenic Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cardiogenic Shock pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cardiogenic Shock.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cardiogenic Shock pipeline depth and focus of Cardiogenic Shock therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Cardiogenic Shock Therapeutic Products under Development, Key Players in Cardiogenic Shock Therapeutics, Cardiogenic Shock Pipeline Overview, Cardiogenic Shock Pipeline, Cardiogenic Shock Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cardiogenic Shock Overview
Therapeutics Development
An Overview of Pipeline Products for Cardiogenic Shock
Cardiogenic Shock Therapeutics under Development by Companies
Cardiogenic Shock Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Cardiogenic Shock Therapeutics - Products under Development by Companies
Cardiogenic Shock Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Cardiogenic Shock Therapeutics Development
Curacyte AG
Cardiogenic Shock - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Molecule Type
Drug Profiles
Hemoximer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pyruvate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cardiogenic Shock Therapeutics – Drug Profile Updates
Cardiogenic Shock - Featured News
Mar 28, 2011: PHOENIX Phase III Trial Of PHP For Distributive Shock To Continue After Positive Midpoint Recommendation From DMB
Jan 10, 2008: Curacyte Receives US Orphan Drug Designation for Cardiogenic Shock Drug, Hemoximer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Cardiogenic Shock, H2 2011
Products under Development for Cardiogenic Shock – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Curacyte AG, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Molecule Type, H2 2011
Cardiogenic Shock Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Cardiogenic Shock, H2 2011
Products under Development for Cardiogenic Shock – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Mid Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Nitric Oxide - Therapeutics, Markets and Companies
• Cardiogenic Shock. American Heart Association Clinical Series
• Sepsis Therapeutics - Global Strategic Business Report
• Lithotripters Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
• Disinfectants - Global Strategic Business Report
• Diabetes Diagnostics - Global Strategic Business Report
• Molecular Diagnostics - Global Strategic Business Report
• Urolithiasis (Urinary Stone) Management Devices Markets Worldwide
• Medical Nutrition - A Global Market Overview
• Blood Banking And Blood Products - Global Strategic Business Report